Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer
In recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in treating metastasized castration-resistant prostate cancer (mCRPC). Several types of research have been published on the therapeutic use of α-emitter radiopharmaceuticals, and several authors s...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/78187 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer
- Bone Seeking Radiopharmaceuticals for Metastatic Bone Pain
- Externally Validated Longitudinal GRU Model for Visit-Level 180-Day Mortality Risk in Metastatic Castration-Resistant Prostate Cancer
- Novel Therapeutic Settings in the Treatment of Castration- Resistant Prostate Cancer
- Current Options and Future Directions in Castrate Resistant Prostate (CRPC)
- Development of Novel Secondary Hormonal Therapies for Castrate-Resistant Prostate Cancer
- New Approaches Targeting Androgen Receptor Signal Pathways for Treatment of Castration-Resistant Prostate Cancer